Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes
Myelodysplastic syndrome (MDS) arises from mutations in hematopoietic stem cells (HSCs). Here, the authors demonstrate that HSCs in higher-risk MDS express the surface marker CD123 and are characterized by activation of protein synthesis machinery and increased oxidative phosphorylation.
Guardado en:
Autores principales: | Brett M. Stevens, Nabilah Khan, Angelo D’Alessandro, Travis Nemkov, Amanda Winters, Courtney L. Jones, Wei Zhang, Daniel A. Pollyea, Craig T. Jordan |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7232188cb74f401c89e6e1606e8171e9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy
por: Blau O, et al.
Publicado: (2014) -
Clonal evolution in myelodysplastic syndromes
por: Pedro da Silva-Coelho, et al.
Publicado: (2017) -
MSI2 is required for maintaining activated myelodysplastic syndrome stem cells
por: James Taggart, et al.
Publicado: (2016) -
TP53 in Myelodysplastic Syndromes
por: Yan Jiang, et al.
Publicado: (2021) -
The genomic landscape of pediatric myelodysplastic syndromes
por: Jason R. Schwartz, et al.
Publicado: (2017)